BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and Phase 2 studies at the International Congress for Ataxia Research in London from November 12-15, 2024.
Nomlabofusp is a cutting-edge protein replacement therapy aimed at addressing Friedreich’s ataxia by delivering frataxin directly to mitochondria. The company will showcase three key posters, including an oral presentation by Dr. Russell Clayton, highlighting the therapy’s impact on frataxin levels and gene expression.
These studies could mark a significant step forward in treatment options for Friedreich’s ataxia, offering hope for improved patient outcomes.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.